Search

Your search keyword '"human papillomavirus DNA tests"' showing total 733 results

Search Constraints

Start Over You searched for: Descriptor "human papillomavirus DNA tests" Remove constraint Descriptor: "human papillomavirus DNA tests" Topic papillomavirus infections Remove constraint Topic: papillomavirus infections
733 results on '"human papillomavirus DNA tests"'

Search Results

1. Primary human papillomavirus testing by clinician- versus self-collection: Awareness and acceptance among cervical cancer screening-eligible women.

2. Parotid squamous cell carcinoma metastases: Application of human papillomavirus-DNA test on liquid-based cytology to recognize oropharyngeal origin of the neoplasm.

3. Triage performance of PAX1 m /JAM3 m in opportunistic cervical cancer screening of non‒16/18 human papillomavirus-positive women: a multicenter prospective study in China.

4. Transcriptionally Active Human Papillomavirus Infection in a Minority of Esophageal Squamous Cell Carcinomas in North America.

5. Comparison of Hybribio-H13 and Hybrid Capture® 2 human papillomavirus tests for detection of CIN2+ and CIN3.

6. Social media use in HPV-, cervical cancer-, and cervical screening-related research: A scoping review.

7. Primary Human Papillomavirus Test Uptake and Cervical Cancer Screening Trends in the Midwest, United States.

8. Home-based self-sampling vs clinician sampling for anal precancer screening: The Prevent Anal Cancer Self-Swab Study.

9. Prediction of carcinogenic human papillomavirus types in cervical cancer from multiparametric magnetic resonance images with machine learning-based radiomics models.

13. 13-Type HPV DNA Test versus 5-Type HPV mRNA Test in Triage of Women Aged 25-33 Years with Minor Cytological Abnormalities-6 Years of Follow-Up.

14. Prevalence of cervical human papillomavirus in Mexico, 2010-2017: analysis of 2.7 million women.

15. Coverage rate of cervical cytology and HPV DNA test for cervix cancer screening: Reappraisal on impact of COVID-19 outbreak.

16. Comparative performance of the human papillomavirus test and cytology for primary screening for high-grade cervical intraepithelial neoplasia at the population level.

17. [Acceptability of self-sampling as a method for cervical cancer screening among women from the Region of Murcia (Spain).]

18. Liquid-based cytology and HPV DNA test in anal specimens from women with cervical cancer.

19. Non-speculum sampling approaches for cervical screening in older women: randomised controlled trial.

20. Accuracy of combined molecular and morphology-based triage for HPV-positive women in routine cervical cancer screening services from Colombia.

21. High Prevalence of Genital Human Papillomavirus Infection in Patients With Primary Immunodeficiencies.

22. Double Positivity for HPV DNA/P16 INK4a Does Not Influence Survival of Patients With Oral Squamous Cell Carcinoma.

23. Human papillomavirus genotyping predicts residual/recurrent disease after local treatment for cervical intraepithelial neoplasia better than viral DNA testing.

24. HPV16 and HPV18 seropositivity and DNA detection among men who have sex with men: a cross-sectional study conducted in a sexual health clinic in London.

25. Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study.

26. Performance and Diagnostic Accuracy of Human Papillomavirus Testing on Self-Collected Urine and Vaginal Samples in a Referral Population.

27. HPV DNA genotyping, HPV E6*I mRNA detection, and p16 INK4a /Ki-67 staining in Belgian head and neck cancer patient specimens, collected within the HPV-AHEAD study.

28. T Cell Receptor Repertoires Acquired via Routine Pap Testing May Help Refine Cervical Cancer and Precancer Risk Estimates.

29. Agreement between careHPV and hybrid capture 2 in detecting high-risk HPV in women in Tanzania.

30. An initiative to assess the quality of Tanzanian cervical cancer specimens for HPV and telomerase detection.

31. DNA Recovery Using Ethanol-Based Liquid Medium from FTA Card-Stored Samples for HPV Detection.

32. HPV Screening Test for the Detection of Precancerous Cervical Lesions and Cervical Cancer in Israeli Women.

33. Quadrivalent human papillomavirus vaccination successfully reduces the prevalence of vaccine-targeted genotypes in a young, vaccine-eligible-age sample of Australian females.

34. Koilocytic changes are not elicited by human papillomavirus genotypes with higher oncogenic potential.

35. Prevalence of human papillomavirus and implication on survival in Chinese penile cancer.

36. Evaluation of the concordance in HPV type between self- and physician-collected samples using a brush-based device and a PCR-based HPV DNA test in Japanese referred patients with abnormal cytology or HPV infection.

37. Implementing the 3T-approach for cervical cancer screening in Cameroon: Preliminary results on program performance.

38. Selecting human papillomavirus genotypes to optimize the performance of screening tests among South African women.

39. Reactions of women underscreened for cervical cancer who received unsolicited human papillomavirus self-sampling kits.

40. Human papillomavirus genotype distribution in genital warts among women in Harare-Zimbabwe.

41. Assessment of micronuclei counts as tumour marker in cervical carcinogenesis: A follow-up study.

42. Prevalence of human papillomavirus in oral gargles and tonsillar washings.

43. Psychosocial impact of inclusion of HPV test on the management of women with atypical squamous cells of undetermined significance: a study within a randomised pragmatic trial in a middle-income country.

44. HPV-positive Squamous Cell Carcinoma of the Larynx, Oral Cavity, and Hypopharynx: Clinicopathologic Characterization With Recognition of a Novel Warty Variant.

45. RNA-based high-risk HPV genotyping and identification of high-risk HPV transcriptional activity in cervical tissues.

46. The role of human papilloma virus test in men: First exhaustive review of literature.

47. Value of CCNA1 promoter methylation in triaging ASC-US cytology.

48. Supplemental Trichomonas vaginalis testing is required to maintain control following a transition from Pap smear to HPV DNA testing for cervical screening: a mathematical modelling study.

49. From presumed benign neck masses to delayed recognition of human papillomavirus-positive oropharyngeal cancer.

50. The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador.

Catalog

Books, media, physical & digital resources